Zimmer Biomet Spine Announces New Milestone for its Mobi-C® Cervical Disc

February 25, 2020 — Zimmer Biomet Spine today announced that over 150,000 MobiC® Cervical Discs have been implanted worldwide.

Zimmer Biomet holds a commanding position in the $200 million global cervical disc market. The Mobi-C device represents an optimal solution with statistical superiority to two-level fusion at seven years.

James Cloar, President of Zimmer Biomet Spine, notes, “Mobi-C is supported with great, long-term clinical data and we are proud to announce this milestone that highlights its market success, as well.”

“The availability of the Mobi-C artificial disc has helped surgeons give patients the best opportunity to maintain motion and avoid a fusion. This leads to faster return to work and lower rates of adjacent level disease,” adds Dr. Michael Hisey, board-certified orthopedic surgeon at Texas Back Institute who was a participant in the Investigational Device Exemption study. “With the Mobi-C one step insertion and mobile core technology, I have a disc that allows me to operate with a familiar technique and I know that the disc motion will adapt to patients with a variety of cervical conditions.”

The Mobi-C Cervical Disc was first implanted in France in 2004 and was approved for sale in the United States by the U.S. Food and Drug Administration in 2013.

About the Mobi-C Cervical Disc

Mobi-C is the first cervical disc prosthesis approved by the FDA for reconstruction of a cervical disc at both one and two levels (C3-C7). Mobi-C is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis that is inserted in a single step, without requiring bone chiseling or other vertebral anchorage such as screws or keels. The Mobi-C Cervical Disc Prosthesis is indicated in skeletally mature patients for reconstruction of the disc from C3-C7 following discectomy at one level or two contiguous levels for intractable radiculopathy (arm pain and/or neurological deficit) with or without neck pain or myelopathy due to abnormality localized to the level of the disc space and at least one of the following conditions confirmed by radiographic imaging (CT, MRI or X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes) and/or visible loss of disc height compared to adjacent levels. The Mobi-C Cervical Disc Prosthesis is implanted using an anterior approach. Patients should have failed at least six weeks of conservative treatment or demonstrated progressive signs or symptoms despite nonoperative treatment prior to implantation of the Mobi-C Cervical Disc Prosthesis.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forwardlooking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

For indications, contraindications, warnings, precautions, potential adverse effects and patient counselling information, see the package insert or contact your local representative; visit http://www.zimmerbiomet.com for additional product information.

Media contact:

Nate Ness


(617) 756-1869

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button